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Peripubertal, leptin-deficient ob/ob female mice were used in an investigation of 
exogenous estradiol (E2) and BIBP3226, a neuropeptide Y (NPY) antagonist acting at the Y1 
receptor, on food consumption, body mass and sexual receptivity.  The absence of leptin in the 
ob/ob model has been proposed to result in chronic hyperphagia due to high levels of NPY 
signaling.  Research findings suggest that NPY Y1 receptors, whether located in the CNS or 
PNS, are likely candidates for mediating the orexigenic actions of NPY.  Moreover, the lack of 
reproductive organ development characteristic of ob/ob mice is proposed herein to be consequent 
of excessively elevated NPY levels activating peripheral Y1 receptors.  Reproductive organ 
development and function were restored by exogenous estradiol administration as well as by a 
combined treatment with BIBP3226 and E2, suggesting a role of E2 in mediating NPY’s effects 
on caloric intake, reproductive development and sexual receptivity.  
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CHAPTER I 
 
INTRODUCTION 
 
 
Heightened awareness of metabolic syndromes has sparked aggressive research to 
identify the underlying mechanisms of obesity.   Researchers have learned that fat 
deposition in mammals is regulated by a complex signaling network that continually 
communicates energy status between the central (CNS) and peripheral nervous systems 
(PNS) [1, 2].  To find new targets for pharmaceutical therapies, researchers are now 
exploring a multitude of CNS and PNS signals that influence metabolism. 
 The hypothalamus has long been known to be the central integration center that 
responds to signals related to the availability of fuel molecules in the body by effecting 
changes in behavior (appetite) and physiology (metabolic rate) [3, 4].  Hypothalamic 
regions, especially the arcuate nuclei (ARC), are richly innervated with both anorexigenic 
and orexigenic neuronal projections [5, 6].  Organismal energy balance is maintained by 
signals from these counter-regulatory pathways that stimulate or inhibit metabolism via 
alterations in caloric intake and in energy expenditure.   Colocalization of the known key 
appetite-regulating pathways, including the appetite-stimulating signals, Neuropeptide Y 
(NPY) and Agouti-related protein (AgRP), as well as the appetite-inhibiting signals, pro-
opiomelanicortin (POMC) and melanocyte-stimulating hormone (MSH), highlight the 
ARC as a key regulatory site of energy balance and metabolism [1-6] .  In addition, 
leptin, a hormonal peptide that has major anorexigenic actions, functions in both the CNS 
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and PNS to signal satiety and to attenuate caloric intake [7-9].  In contrast, NPY is a 
protein that works as a neuronal transmitter or modulator to exert potent orexigenic 
actions: it stimulates hunger sensations and increases energy intake [11, 12].  
The dynamic relationship between the leptin and the NPY systems maintains 
energy homeostasis and helps to effect the long-term maintenance of a relatively constant 
body mass (Figure 1) [2, 3].  Manipulation of the opposing actions of these networks in 
the CNS has been the focus of extensive research toward pharmaceutical attempts to treat 
obesity.  However, the roles of these energy-regulating signals in the PNS are not well 
understood.   
Adequate nutrition is a prerequisite for normal reproductive development.  Energy 
deficits or excess, in the form of adipose tissue, typically halt reproductive functions, 
especially in female mammals, where the estrous cycle and sexual behavior can be 
disrupted by malnutrition [14, 15].  Metabolic hormones and neuronal signals, including 
leptin and NPY, and steroid hormones, such as estradiol, dynamically regulate metabolic 
changes, alter food intake, energy expenditure, adiposity, fertility and reproductive 
behavior [4-6].   Sufficient energy reservoirs, in the form of adipose tissue, are necessary 
to ensure adequate energy supply and reproductive success [10-12].   Limited energy 
supplies in the form of adipose tissue require physiological alterations to support 
organismal survival [14].   In times of severely limited energy stores (fasting), fertility 
and reproductive behavior are eliminated in favor of energy utilization for basic 
organismal needs and survival [14-15].    
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Reproductive behavior has a large cost in energy transfer.  Adequate stores of 
chemical energy are thus critical to support reproductive behavior.  Correspondingly, 
reproductive functions are minimized during energetic challenges [14, 21].  Extreme 
metabolic conditions are characterized by minimal adipose tissue, as seen in patients with 
anorexia nervosa.  Surprisingly, excess adipose tissue, as seen in obese individuals, can 
also induce a similar stress response resulting in a state of nutritional infertility [13]. 
Extreme metabolic stress, whether due to abnormal leanness or obesity, inhibits the 
hypothalamic-pituitary-gonadal axis in female mammals: the resulting decrease of 
gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus suppresses 
luteinizing hormone (LH) release,  halting ovulation and ultimately inhibiting the 
synthesis of ovarian steroid hormones, thus halting the expression of female sexual 
behavior [11,13, 22]. 
 Due to the continual interaction between metabolic and reproductive cues, a 
minimal alteration in one system parallels significant changes in the other.  Continual 
crosstalk exists between these dynamic signaling systems [23].  In times of fasting, 
elevated circulating leptin levels attenuates estrogen signaling via target receptors in the 
arcuate nucleus of the hypothalamus, thus reducing the secretion of  luteinizing hormone 
and follicle-stimulating hormones (LH & FSH) release, thus preventing estrous cycling 
[23], clearly supporting the effects of metabolic cues on reproductive ability (in 
mammals) [24, 25].    
Sexual receptivity in female rodents is characterized by lordosis, an estrogen-
dependent behavior that signals copulatory readiness to males [4]. Lordosis frequency 
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increases with estrogen dose [27].  Estrogens, in part, contribute to sexual behavior by 
stimulating specific hypothalamic brain regions, especially the ventromedial nucleus 
(VMN) of the hypothalamus and ARC [27, 28].  The area of specific interest in this study 
is the ARC, which is richly innervated with estrogen- and leptin- sensitive neuronal 
projections. Estrogen and leptin elicit behavioral changes in sexual behavior as a 
consequence of binding to their target receptors in these hypothalamic regions [5].   
The presence of anorexigenic leptin inhibits appetite and enhances the expression 
of sexual behavior in female hamsters.  In times of fasting, sexual behavior is absent thus 
preventing fertility [13].  Similar to wild-type mice in a severely fasted state, ob/ob mice 
are sexually non-responsive and are infertile [27].  As expected, leptin treatments 
alleviate reproductive impairments [23], thus implicating a critical role for leptin not only 
in fat deposition but also in regulating reproductive behavior and therefore evolutionary 
success.  Previous studies have revealed that leptin treatments will promote sexual 
behavior in fed but not fasted rodents, suggesting a role of leptin as a potential sex signal 
[9].  In further support of a role for leptin as a reproductive signal, inhibition of lordosis 
was found to be intensified in food deprived, fasting rodents [9, 10, 29, 30].  Since leptin 
levels have a positive correlation with body fat mass, reproductive behavior and sexual 
responsiveness may be in part heightened by increased caloric stores in the form of 
adipose [9, 10,30].  When female mammals have inadequate or excess calories, 
reproductive behavior and fertility are impaired.   
The mechanistic interactions of leptin with other metabolic cues, including 
estrogen and NPY, to alter reproductive behavior are highly complex and remain poorly 
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understood.  Previous work by Wade et al. identified a significant reduction in lordosis 
duration in estrogen-treated, food-deprived wild-type rodents [9, 30].  Similarly, 
combined treatments of leptin and estrogen did not alter lordosis behavior in food-
deprived rodents [9].  However, leptin treatment alone has been found to significantly 
shorten lordosis duration in food-deprived animals [9, 30].  Based on these findings, food 
deprivation or inadequate energy stores appears to override the influence of estrogen and 
leptin to increase lordosis duration.  
 
Estrogen 
The ovarian sex steroid, estradiol (E2), has a crucial role in normal reproductive 
organ development and puberty onset [32].  Moreover, E2 exerts an anorexigenic, leptin-
like effect on energy homeostasis via estrogen receptors that are broadly distributed 
throughout the ARC, in parallel with receptors for leptin and NPY (described below, 
Figure 2) [9, 33].  The exact anorexigenic actions of E2 in the CNS and PNS remain 
unclear, but an interaction with the leptin-dependent melanocortin system appears likely, 
as described below (Figure 3) [9, 26].  Estradiol is known to have anorectic effects on 
food intake and it can reduce adiposity [33, 34].  Administration of exogenous estradiol 
in ovariectomized rodents as well as rodents with intact ovaries reduces food intake and 
body mass [29].  Work by Gao et al. suggested that E2 substantially increases excitatory 
inputs onto POMC neurons of the ARC in normal phenotype rodents [34].  Synaptic 
rearrangement has been found to occur independently of leptin in wild-type, ob/ob mice 
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and leptin receptor deficient db/db mice [29].  Moreover, body weight reductions induced 
by E2 treatments were linked to Stat 3 activation in the brain [34].   
Hormonal changes in the ARC may determine body weight regulation and could 
be a potential pharmaceutical target for obesity. Intracerebroventricular (icv) 
administration of estradiol into regions of the ARC, including the medial preoptic nucleus 
(MPN) and paraventricular nuclei (PVN), caused decreased caloric intake and food mass 
[3, 9].    These hypothalamic regions are heavily innervated with neuronal networks 
sending orexigenic and anorexigenic signals that maintain energy homeostasis.     
E2 treatments have been found to increase c-fos expression in POMC neurons in the ARC 
[13].  E2 appears to have an anti-obesity effect that can be expressed independently of 
leptin-based pathways, as evident by results showing a significant decrease in body 
weight in leptin-deficient (ob/ob) and leptin-receptor  deficient (db/db) mice over a 24 
day treatment [13, 29].  Moreover, a fifty percent reduction in weight gain was evident 
after 4 weeks in male and female mice treated with estradiol [13].  
Administration of E2 to rodents reduces their caloric intake and body mass by 
enhancing energy expenditure [4-6, 36].  Disruption of the aromatase enzyme gene, thus 
blocking the conversion of androgens to estrogens, results in an obese phenotype in 
rodent models [16, 17].  Further supporting the hypothesis that estrogen resistance results 
in adiposity, estrogen alpha-receptor (ER-α) knock-out mice have been reported to 
exhibit an obese phenotype [13, 35, 37]. Previous studies of the estrogen receptors, ER-α 
and ER-β, using estrogen receptor knockout-mice, have linked ER-α gene deletion to 
increased body weight and insulin resistance [37].  Inactivation of the ER-α receptor in 
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rodent models results in a hundred-fold increase in fat mass, thus suggesting a role for 
ER-α in maintaining a lean phenotype [13].  In the absence of ER-α, estrogen does not 
reduce food intake or body weight [13].  Estrogen mediation or activation of 
melanocortin pathways via ER-α may explain its anorectic effects [38].   
Similar to the ER-α knockout phenotype, leptin-deficient ob/ob mice exhibit 
insulin resistance partnered with extreme obesity, and develop huge adipose stores [37].  
Both models implicate a critical role for estrogen signaling, likely through the ER-α 
receptor, in mediating its anorexigenic actions to maintain energy homeostasis and a 
normal body mass [17, 35].  It is evident that in the absence of estrogen ER-α signaling, 
as seen in the ER-α knock-out mouse, leptin signaling alone is insufficient to maintain a 
normal body mass.  The fact that leptin-deficient ob/ob mice exhibit impaired estrogen 
signaling, suggests an interaction between leptin and estrogen pathways in maintaining a 
normal body mass phenotype.  Similarities between the anorectic actions of leptin and 
estrogen suggest they both may affect the same neuronal targets in the hypothalamus, and 
in peripheral organs [9].  Theoretically, exogenous estradiol administration would have a 
restorative effect in leptin-deficient mice in attenuating appetite and reducing body mass, 
as well as stimulating estrus and mating.  This question is a key objective of this study 
(see Chapter II). 
Several studies suggest that E2 has direct effects on hypothalamic neurons, 
specifically leptin- and NPY-modulated neurons [39, 40].  Hypothalamic NPY 
concentrations significantly increase in number after ovariectomy in rodents, followed by 
significant body weight increase over 10 weeks, suggesting that E2 inhibits NPY 
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synthesis and/or release and thereby mediate the effects of NPY on energy homeostasis 
[29].  Similarly, researchers have demonstrated that estrogen deficiency leads to 
hyperleptinemia, thus E2 is implicated in the excitatory and inhibitory signaling actions of 
leptin and NPY, respectively [9].  Ovariectomized rodents, in the absence of estrogens, 
require extremely high leptin doses before they will begin to reduce body mass [29].  
These findings suggest that estrogens are potent mediators of the metabolic signals leptin 
and NPY, and suggest the basis for a molecular mechanism by which E2 exerts strong 
influences on both metabolism and food intake.  
A dual function of estrogen as a modulator of reproductive organ development 
and sexual behavior ties in with its anorexigenic actions to maintain energy homeostasis 
(Figure 4).  Thus, estrogens might be a tool used to identify issues in nutritional 
infertility.  Though estrogen does not solely dictate metabolic and reproductive ability, its 
interactions with other major endocrine/hormonal signals requires clarification to identify 
and treat physiological disruptions that hinder metabolism and reproductive ability. 
 
Leptin  
 Leptin, a protein secreted from adipocytes in amounts proportionate to the amount 
of adipose tissue, decreases caloric intake and stimulates energy expenditure by 
interactions with its receptors in the ARC of the hypothalamus [7].  Leptin receptors, in 
five receptors, Ob-Ra through Ob-Re, are widely distributed throughout the CNS and 
PNS, but are heavily concentrated in the ARC and PVN, where they exert anorexigenic 
actions by two proposed pathways [9].  Leptin receptors are co-localized in the 
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hypothalamus with NPY, AgRP, and POMC neurons [7].  Leptin-based modulations of 
food intake and body mass are partially due to its actions in the hypothalamus, where it 
interacts with OB-Ra to stimulate the synthesis of anorexigenic peptides (Figure 3) [7].  
High circulating concentrations of leptin secreted from active adipocytes act in the ARC 
to stimulate anorexigenic neurons to ultimately increase synthesis and release of POMC 
cleavage products, including α-melanocyte-stimulating hormone (α-MSH) [2, 18].  
Alpha-MSH binds to its receptors, MC3R and MC4R, to signal satiety, decrease caloric 
intake and activate pathways that increase energy expenditure [41].  Leptin’s stimulation 
of α-MSH also inhibits orexigenic NPY-signaling in the hypothalamus, via leptin 
receptors distributed on NPY-containing neurons within the ARC [9, 42]. 
 Further support of the counter-regulatory roles of leptin and NPY comes from the 
observation that exogenous leptin can reduce the quantity of NPY mRNA in vivo and 
NPY release in vitro [43].  NPY neuronal firing is increased threefold during fasting, and, 
as expected, it is inhibited by leptin administration [7].  Considering the impact that leptin 
exerts on NPY production and release, it is reasonable to believe that the hyperphagic, 
obese and infertile phenotype of the leptin-deficient ob/ob mouse is the consequence of 
excessive, chronic NPY signaling due to the chronic lack of leptin’s inhibitory actions on 
the NPY signaling. 
 
Neuropeptide Y 
 NPY is the most potent orexigenic peptide identified to date.  NPY activity leads 
to conservation of the body’s energy reservoirs by reducing energy expenditure and by 
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enhancing appetite [19, 20, 49].  NPY acts on at least six receptor subtypes 
(Y1throughY6) distributed centrally within the ARC of the hypothalamus and in 
peripheral tissues including adipose, ovaries, small intestine and liver [12, 20].  Continual 
intracerebroventricular (icv) administration of NPY or an NPY analog results in a 
perceived sense of starvation and induces hyperphagia.  Even in animals that have fed to 
satiation, exogenous NPY administration induces hyperphagia and reduces the activity of 
the sympathetic nervous system, thereby reducing the overall metabolic rate [42, 45, 46].  
In addition, the extremely obese phenotype of the ob/ob mouse model is associated with 
the over-expression of hypothalamic NPY [20].  The mating of male ob/ob mice with 
female NPY knockout mice produces progeny that exhibit a 50% reduction in adipose 
tissue compared to the ob/ob parents [9].  Moreover, increases in hypothalamic NPY 
RNA and decreases in POMC RNA are normalized following leptin treatment in the 
ob/ob model [7].  Under chronically elevated NPY signaling, increased food consumption 
and decreased energy expenditure promote positive energy balance and lead to increased 
body mass, as seen in the ob/ob phenotype.  
 Identification of the specific NPY receptor that mediates its orexigenic effects is 
relevant for developing effective drugs to treat obesity.  Experiments suggest that 
hyperphagia in the ob/ob mice might be due to continual stimulation of NPY on the Y1 
receptors [12].  Genetic disruption of the Y1 receptor allele in ob/ob mice reduced 
appetite and initiated activity in the gonadotrope axis [25, 39].  Both wild-type and Y1 
receptor knockout mice start life with equivalent birth weights, but Y1 receptor knockout 
mice weigh less than wild-type controls by the time of weaning (21 days of age) [10].  
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The Y1 receptor proposed to mediate orexigenic NPY actions is the target of this 
experimental design and supported by previous findings suggesting a potential dual 
function of the NPY-Y1 receptor activation in both energy homeostasis and reproductive 
organ development [47].  The reduced weights of seminal vesicles and reduced levels of 
pituitary LH contents in ob/ob male mice are restored to normal in offspring of ob/ob 
mice mated to NPY Y1 receptor knockout mice [25].  These findings further implicate an 
inhibitory role for Y1 receptor activation on the HPG axis [25]. 
 The presence of sex steroids might be a prerequisite for NPY mediation of 
reproductive organ development.  In the absence of sex steroids, icv administration of 
NPY inhibits LH release in the wild-type phenotype, suggesting a sex-steroid dependent 
action of NPY on the HPA axis to modulate reproductive development [39].  A direct 
mechanism by which sex steroids alter NPY gene expression is not yet established, but 
likely changes NPY and/or NPY receptor synthesis and release [39].  In food restricted 
conditions, Y1 receptor knockout mice appear to be protected against gonadotrope axis 
disruptions unlike wild-type controls that exhibit delayed puberty and low circulating 
levels of LH,  further supporting the role of Y1 receptor activation in the inhibition of 
reproductive development [10, 48].   
With increased attention towards the obesity epidemic, characterizing the 
peripheral role of NPY in energy homeostasis is critical for the development of 
pharmaceutical interventions in this system.  There is strong evidence suggesting that 
NPY modulates metabolism by stimulating energy intake, and alters reproductive 
development and behavior, via an unidentified NPY receptor subtype [49].  The role of 
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NPY taken together with evidence that Y1 receptor activation leads to impaired 
metabolism and reproductive development, focuses attention on the Y1 receptor as the 
primary target for understanding the orexigenic effects of NPY.   
  
Ob/ob Model 
Ob/ob mice are characterized by chronic hyperphagia, a continuous sense of 
perceived starvation, morbidly obese phenotype and lack of reproductive maturation.  
Not only do they remain infertile, adults continue to consume twice the calories and 
weigh up to twice the body mass of wild type mice [27].  This model provides insights 
for identifying the underlying regulators in the complex networks that control energy 
homeostasis/metabolism and reproduction.   
Continual crosstalk exists between neuroendocrine regulators of energy 
homeostasis and reproduction.   Furthermore, several regulating hormones, including 
estrogen, leptin and NPY, have dual functions in communicating energy and reproductive 
ability as well as similar neural signaling targets (ARC) [3].  Knowing that food 
availability directly affects metabolism and reproductive behavior, it is reasonable to 
conclude that excess calories, stored in the form of adipose, could also affect fertility and 
reproductive ability.  However, the impaired reproductive organ development 
(maturation) and absence of estrus in ob/ob female mice alludes to endocrine signaling 
disruptions as a possible underlying mechanism in infertility (Figure 5).   
 Food availability is a general indicator/predictor of reproductive success, 
especially in female mammals where pregnancy and lactation can require a doubling (or 
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more) of metabolic rate.  However, the leptin-deficient ob/ob model presents the opposite 
case, i.e., where energy excess impairs reproductive development and functioning.  More 
likely, disruption of one or more of the major hormones, leptin, estrogen and/or NPY, 
halts network communication and reduces reproductive signaling [13].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 FIGURE 1:  Overview of the leptin-deficient ob/ob mouse model. 
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FIGURE 2:  E2 and leptin presence or absence on phenotype.  
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FIGURE 3:  Expected physiological changes in the ob/ob mouse when administered  
            exogenous E2. 
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FIGURE 4:  E2 modes of action in the central and peripheral nervous system. 
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FIGURE 5:  Hypothalamic changes that influence puberty. 
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Hypothesis 
 
This study on female mice lacking leptin, a major anorexigenic signal in 
mammals, examined the role of NPY signaling in the periphery.  A fundamental 
assumption underlying the proposed work is that the absence of leptin in the ob/ob model 
results in NPY-mediated chronic hyperphagia, an obese phenotype and reproductive 
impairments.  I manipulated NPY and estrogen signaling in the leptin-deficient mice to 
evaluate the interrelationship between leptin, NPY and estrogen.  Previous research 
suggests that NPY Y1 receptors, whether located in the CNS or PNS, are likely 
candidates for mediating the orexigenic action of NPY [25].  Moreover, the lack of 
reproductive development in ob/ob mice is hypothesized to be the consequence of 
elevated NPY levels.  If so, reproductive development might occur after inhibition of 
NPY Y1 receptors in combination with E2 administration.  The role of E2 in mediating 
NPY effects on caloric intake and reproduction were also assessed.   
 
 
Specific Aims 
 
1.     I propose that elevated NPY signaling in fasted wild-type mice parallels elevated 
NPY signaling in leptin-deficient mice, such that increase appetite in both cases is the 
response to increased Y1 receptor activation by NPY [25, 39, 42].  To determine whether 
or not hyperphagia and obesity in the ob/ob mouse model could be ameliorated by 
blocking NPY signaling, the NPY Y1 receptor antagonist, BIBP3226, was administered 
to prepubertal female ob/ob mice.    Female ob/ob mice received BIBP3226 via 
intraperitoneal (ip) injections twice daily at 12 hour intervals for 14 consecutive days, 
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while body mass and food consumption were measured twice daily.  If injecting the 
antagonist reduces food intake and body mass, these data will support the hypothesis that 
high levels of NPY signaling contribute to hyperphagia and the resultant obesity in 
leptin-deficient mice (Table 2, Box 2).   
 
2.  I propose that E2 exerts anorexigenic effects in leptin-deficient mice.  Preliminary 
findings from my previous experiment support the hypothesis that the leptin-independent 
actions of exogenous E2 reduce caloric intake and body mass in female ob/ob mice. To 
confirm the anorexigenic actions of E2, 17β-estradiol was administered to prepubertal 
female ob/ob mice.  Female ob/ob mice received 17β-estradiol dissolved in sesame-oil 
vehicle via subcutaneous injections twice daily.  Injections occurred every 12 hours for 
14 consecutive days, while body mass and food consumption were measured twice daily.  
At the end of 14 days of treatment, ovarian and uterine measurements were taken.  If 
exogenous E2 reduces food intake and body mass, my previous work suggesting an 
anorexigenic action of E2 will be confirmed (Table 2, Box 3). 
 
3.    I propose that exogenous E2 administration and Y1R inhibition in leptin-deficient 
mice each have additive effects in reducing food intake and body mass.  To characterize 
the relationship between E2 and NPY, both 17β-estradiol and NPY Y1R antagonist were 
administered, as the “combination treatment,” to prepubertal female ob/ob mice.  17β-
estradiol and BIBP3226 were administered peripherally via subcutaneous and 
intraperitoneal injections, respectively.  Each treatment (17β-estradiol & BIBP3226) was 
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administered twice daily, totaling 4 injections per day per animal, every 12 hours for 14 
consecutive days.  If the combined treatment of E2 and BIBP3226 reduces food intake 
and body mass, then these data will support the hypothesis that there is an interaction 
between E2 and the Y1 receptor subtype in mediating energy balance in the leptin-
deficient model (Table 2, Box 4).   
 
4.  I propose that elevated NPY signaling inhibits the reproductive axis in leptin-deficient 
female mice by means similar to the reproductive inhibition that has been observed in 
fasted wild-type mice.  To determine whether or not reproductive development in the 
ob/ob mouse model results from leptin absence and/or from increased NPY signaling, the 
NPY Y1 receptor antagonist was administered to female ob/ob mice.  Female ob/ob mice 
received BIBP3226 via intraperitoneal injections twice daily at 12 hour intervals for 14 
consecutive days.  Following 14 days of treatment, ovarian and uterine weights were 
compared between treatment groups.  If treatment with the Y1R antagonist is associated 
with increased uterine and ovarian mass, then these data will support the hypothesis that 
high levels of Y1R activation impairs reproductive development (Table 2, Box 2). 
 
5.  I propose that E2 exerts uterotrophic effects in leptin-deficient mice.  Theoretically, 
leptin absence and/or elevated NPY signaling results in impaired reproductive organ 
development by inhibiting endogenous E2   signaling in leptin-deficient mice.  My 
previous findings demonstrated that exogenous E2 administration to female ob/ob mice 
was associated with reproductive organ development that was comparable to that of wild-
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type mice.  To confirm the role of E2 on reproductive development, 17β-estradiol was 
administered to prepubertal female ob/ob mice at the dose indicated in aim 3.  Ovarian 
and uterine measurements were taken as described previously.  If exogenous E2 
administration is associated with increased uterine and ovarian mass, these data will 
support the hypothesis that E2 signaling influences hypothalamic peptide levels, leptin 
and NPY, and contributes to reproductive development in ob/ob mice (Table 2, Box 3).  
 
6.  I propose that exogenous E2 administration and Y1R inhibition will contribute in 
additive fashion to promote uterine and ovarian development in leptin-deficient mice.  To 
characterize the combined effects of E2 and NPY blockade on reproductive development 
in the absence of leptin, both 17β-estradiol and NPY Y1R antagonist were administered 
to prepubertal female ob/ob mice.  17β-estradiol and BIBP3226 were administered 
peripherally via subcutaneous and intraperitoneal injections, respectively.  Each treatment 
(17β-estradiol or BIBP3226) was administered twice daily, totaling 4 injections per day 
per animal, every 12 hours for 14 consecutive days.  Following euthanasia, ovaries and 
uteri were collected for analysis.  If the combined treatment of E2 and BIBP3226 
enhances reproductive development to the extent that uterine masses exceed that 
observed in response to either E2 or the Y1 receptor antagonist, then these data support 
the hypothesis that combined E2 signaling and Y1 receptor blockade is a more potent 
signal for reproductive development in the leptin-deficient model than either treatment by 
itself (Table 2, Box 4).   
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7.  I propose that Y1R activation inhibits reproductive behavior in leptin-deficient mice.  
To understand the impact of Y1R activation on reproductive behavior, female ob/ob mice 
were tested for sexual receptivity following a twelve day treatment of Y1R antagonist.  
Following treatment on day thirteen, each female ob/ob mouse was tested for sexual 
receptivity in a 10 minute test with a sexually active wild-type male, followed by an  
extended sexual behavior test occurring on treatment day 14 where each female ob/ob 
mouse was paired with the same stud male for 12 hours.  Following the 12 hour 
behavioral testing, all female mice were euthanized via CO2 asphyxiation and the 
presence or absence of a vaginal seminal plug was noted.  If Y1R antagonist 
administration restores sexual receptivity in female ob/ob mice, this would support the 
hypothesis that high levels of Y1R activation are responsible for the absence of sexual 
receptivity in the ob/ob mouse (Table 2, Box 2). 
 
8.  I propose that elevated NPY signaling impairs the effects of endogenous E2 on 
reproductive behavior in leptin-deficient mice.  To identify the role of E2 on reproductive 
behavior, female ob/ob mice were tested for sexual receptivity following a twelve day 
17β-estradiol treatment.  Following treatment on day thirteen, each female ob/ob mouse 
was tested for sexual receptivity in a 10 minute test with a sexually active wild-type male.  
Extended sexual behavior testing occurred on treatment day 14.  Each female ob/ob 
mouse was paired with the same stud male for 12 hours.  Following 12 hour behavioral 
testing, as described in aim 7, all female mice were euthanized via CO2 asphyxiation and 
the vaginal opening was assessed for the presence or absence of seminal plug, an 
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indicator of copulation.  If exogenous E2 administration restores reproductive behavior in 
female ob/ob mice, these data will support the hypothesis that endogenous E2 signaling 
causes sexual receptivity in ob/ob females (Table 2, Box 3).   
 
9.   I propose that the combination treatment of E2 and BIBP3226 will work in additive 
fashion to enhance sexual receptivity in leptin-deficient mice.  To determine the 
significance of exogenous E2 and Y1R activation on reproductive behavior, female ob/ob 
mice were tested for sexual receptivity following a twelve day treatment of 17β-estradiol 
and BIBP3226.  Following treatment on day thirteen, each female ob/ob mouse will was 
tested for sexual receptivity in a 10 minute test with a sexually active wild-type male.  
Extended sexual behavior testing occurred on treatment day 14.  Each female ob/ob 
mouse was paired with the same stud male for 12 hours. As mentioned above, following 
12 hour behavioral testing, all female mice were euthanized via CO2 asphyxiation and 
vaginal opening was assessed for the presence or absence of seminal plug, an indicator of 
copulation.  If the combined treatment of E2 and Y1R antagonist increases sexual 
receptivity in female ob/ob mice more than either treatment by itself, then these results 
would support the hypothesis that E2 signaling andY1R inhibition interact to promote 
higher levels of reproductive behavior in ob/ob mice (Table 2, Box 4). 
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TABLE 1:  Specific Aims 
 
Specific Aims 
1. NPY Y1 receptor blockade decreases food intake and decrease body mass in the 
ob/ob mouse model . 
2.  Exogenous E2 reduces food intake and reduces body mass in the ob/ob mouse 
model. 
3.  The combination treatment, BIBP3226 and E2, has an additive effect to reduce 
food intake and body mass. 
4.  NPY Y1 receptor blockade restores reproductive development (uterine 
hypertrophy) in the ob/ob mouse model. 
5.  Exogenous E2 restores reproductive development in the ob/ob mouse model. 
6. The combination treatment, BIBP3226 and E2, has an additive effect to restore 
reproductive development in the ob/ob mouse model.  
7.  NPY Y1 receptor blockade restores reproductive behavior in the ob/ob mouse 
model. 
8.  Exogenous E2 restores reproductive behavior in the ob/ob mouse model. 
9.  The combination treatment, BIBP3226 and E2, has an additive effect to restore   
reproductive behavior in the ob/ob mouse model. 
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TABLE 2:  Proposed effects of 17-β estradiol (E2) and Y1R-selective NPY antagonist   
                    (BIBP3226) on behavior and physiology of leptin-deficient female mice. 
 
  
Y1R Antagonist Absent 
 
 
Y1R Antagonist Present 
 
E
2 A
bs
en
t 
BOX 1 
 
 
Abnormal Phenotype of Ob/Ob Mice: 
Hyperphagic 
Obese 
Underdeveloped Reproductive Organs 
Absence of Reproductive Behavior 
 
BOX 2 
 
 
Less Hyperphagic vs. Box 1 
Reduced Body Mass vs. Box 1 
Increased Reproductive Organ Mass  
     vs. Box 1 
Presence of Reproductive Behavior  
     vs. Box 1 
 
E
2 P
re
se
nt
 
BOX 3 
 
 
Less Hyperphagic vs. Box 1 
Reduced Body Mass vs. Box 1 
Increased Reproductive Organ Mass  
     vs. Box 1 
Presence of Reproductive Behavior  
     vs. Box 1 
 
BOX 4 
 
 
Less Hyperphagic vs. Box 2 or 3 
Reduced Body Mass vs. Box 2 or  3 
Increased Reproductive Organ Mass  
     vs. Box 1 
Presence of Reproductive Behavior  
     vs. Box 2 or 3 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
 
Animals 
 
Physiological studies were conducted on 60 female mice to investigate the 
relationship between sex hormones, hypothalamic neuropeptides, obesity and 
reproductive fertility.  Female leptin-deficient (ob/ob) mice (B6.V-Lepob) were obtained 
from Jackson Laboratories (Chicago, IL).  All animals were housed in the UNCG -ACUC 
approved animal facility with 12 hour light/12 hour dark cycles and maintained on ad 
libitum food and water (Purina Lab Pellets).  At age 28 days, mice were housed 
individually and were randomly assigned to one of the four treatment groups described 
below (Table 3).  Food intake and body mass were monitored twice daily until age 42 
days.  Prior to experiment, all procedures were approved by the UNCG-ACUC 
committee. 
 
 
TABLE 3: Treatment Groups- see Table 4 for doses 
Treatment Group Number
Vehicle 15 
E2 15 
BIBP3226 15 
Combination 15 
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Treatment 
This study included four treatment groups with fifteen female leptin-deficient 
mice in each group (Tables 3 and 4).  Mice in the control treatment group received 
intraperitoneal injections of saline vehicle and subcutaneous injections of sesame-oil 
vehicle.  Mice in the estradiol group received intraperitoneal injections of saline vehicle 
and subcutaneous injections of 17-β estradiol.  Mice in the NPY antagonist group 
received intraperitoneal injections of BIBP3226, an antagonist to NPY at Y1 receptors, 
and subcutaneous injections of oil vehicle.  Mice in the combination group received 
intraperitoneal injections of BIBP3226 and subcutaneous injections of 17-β estradiol.  All 
mice received two intraperitoneal and two subcutaneous injections per day, at 12 hour 
intervals, for 14 consecutive days (Table 4 & Figure 6).   
 
TABLE 4:  Treatment dose by group. 
 
Treatment Group Treatment Dose 
Vehicle 
0.05 ml saline vehicle 
0.05 ml sesame oil vehicle 
E2 
0.05 ml saline vehicle 
0.05 mg estradiol benzoate in 0.05 ml sesame oil 
BIBP3226 
0.10 mg of BIBP3226 in 0.05 ml saline 
0.05 ml sesame oil vehicle 
Combination 
0.10 mg of BIBP3226 in 0.05 ml saline 
0.05 mg estradiol benzoate in 0.05 ml sesame oil 
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Behavioral Testing 
 
 On the last two days (days 13 and 14) of the experiment, female mice were 
behavioral tested with sexually-experienced (stud) males.  At the onset of the scotophase 
on day 13, each female mouse was placed into the cage of a stud male for 10 minutes 
(Figure 7).  The presence or absence of reproductive behavior was monitored for duration 
of 10 minutes; however, no mating occurred during this 10 minute interval on day 13.    
Following the final injections on day 14, each female mouse was housed for 12 hours 
with its stud male. After euthanasia, using carbon dioxide inhalation, each female was 
assessed for copulatory behavior as evidenced by an intravaginal seminal plug.  At 
necropsy, uteri were dissected and cleaned of fat and weighed to the nearest 0.01mg.  For 
data analysis uterine mass was standardized to mg uterus/25 g body mass. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7:  Behavioral test to monitor sexual receptivity of female leptin-deficient mice 
           with stud male. 
♀
♂
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Statistics 
 
 All statistical analyses were performed with SPSS 15.0 software.  Kolmogorov-
Smirnov tests were used on all data sets to test for normality.  Three variables met the 
criterion for normal distribution: daily food intake, daily body mass and uterine mass. 
Average daily food intakes, terminal food intake, average daily body mass and terminal 
body mass were calculated for each week and the data were analyzed using repeated 
measures ANOVA to account for time effects among the treatment groups.    Treatment 
effects on food intake and body mass were analyzed by one-way ANOVA with post hoc 
comparisons using Tukey’s test.  Uterine mass was expressed as mg of uterine tissue 
mass/ 25g body mass.  Adjusted uterine mass was analyzed using a univariate ANOVA 
with post hoc comparisons by the Duncan’s Multiple Range test.  The results are 
expressed as mean ± S.E.M.   For all statistical tests, a p value < 0.05 was considered 
statistically significant. 
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CHAPTER III 
 
RESULTS 
 
 
Food Intake Analysis 
 
Daily Food Intake 
 
 One-way ANOVA of food intake indicated statistically significant treatment 
effects across the full duration (14 days) of the experiment (p-value<0.001, Tables 3 and 
4; Figure 8).  Subsequently, post hoc comparisons using Tukey’s test resulted in the 
distinction of two groups of mice.  In the first group, the average food intakes of mice 
which received either vehicle or BIBP3226 were statistically equivalent (Table 5, Figure 
9).  Ob/ob mice in the vehicle group consumed an average of 1.32 g of food per day, and 
mice in the BIBP3226 consumed an average of 1.46 g of food daily.  The average food 
intakes of mice in the second group, those which received E2 or combination treatment, 
were significantly lower than those of the first group (Table 5, Figure 9).  The mice who 
received E2 treatments consumed 0.83 g of food on average per day, and the mice in the 
combination treatment group consumed and average of 0.78 g of food per day. 
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TABLE 5:  F and p values for time and treatment effects on average food intake.  
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  FIGURE 8: Daily food intake of female leptin-deficient mice. 
 
 
 
  TABLE 6:  Average weekly food intake for week 1 and week 2 (p-value <0.001). 
                      a,b Means with different superscript letters are significantly different. 
 
 
Week n Average Food Intake;Mean (±SEM) g/day 
1 59 0.93 (±0.03)a 
2 59 1.29 (±0.04)b 
 
 
Effect F-value p-value 
Time F (1,55)= 57.529 <0.001 (see Figure 7, Table 6) 
Treatment F (3,55)=19.495 <0.001 (see Figure 8, Table 7) 
Time x Treatment F (3,55)=21.127 <0.001 (see Figure 9, Table 8) 
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FIGURE 9:  The effects of drug treatment on daily food intake (average of all days) 
  in leptin-deficient mice.  Different letters indicate statistically significant      
  differences.   
 
 
 
TABLE 7:  Mean (±SEM) daily food intake by treatment group for leptin-deficient mice. 
         a,b Means with different superscript letters are significantly different 
 
Treatment n 
Daily Food Intake 
(Total Average); 
Mean (±SEM) g/day 
Vehicle 14 1.32 (±0.05)a 
E2 15 0.83 (±0.03)b 
BIBP3226 15 1.46 (±0.08)a 
Combination (17-β Estradiol & BIBP3226) 15 0.78 (±0.03)b 
   
 
 
 
 
 
  a   a 
 b  b 
 Vehicle                                E2                              BIBP3226                    Combination 
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FIGURE 10:  Food intake by age for each treatment group. 
 
 
 
TABLE 8:  Average weekly food intake by treatment group. 
         a,b,c Means with different superscript letters are significantly different. 
 
 
Treatment n Week 1 Average Food Intake;Mean (±SEM) g/day 
Week 2 Average Food Intake;
Mean (±SEM) g/day 
Vehicle 14 1.08 (±0.05)a 1.66 (±0.07) c   
E2 15 0.83 (±0.04) b 0.84 (±0.04) b 
BIBP3226 15 1.01 (±0.08) a 1.92 (±0.12) c 
Combination 15 0.78 (±0.04) b 0.78 (±0.04) b 
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To discern more precisely the time course of response to these treatments, an 
additional analysis was conducted.  An inspection of Figure 10 suggested that it would be 
productive to compare week 1 with week 2.  Accordingly, two different comparisons 
were made.  The first statistical analysis compared the data averages of week one with the 
averages of week two.  The second comparison compared data from the end of week one 
with data from the end of week two. 
  
 
Average Weekly Food Intake of Week 1 and Week 2 
 
 Repeated measures ANOVA was used to analyze the effects of treatment (vehicle, 
E2, BIBP3226, or combination) and two time points corresponding to the averages of 
each of the two weeks during which food intake was measured, as well as the interaction 
between these two factors (Table 5).  As reported previously (in Daily Food Intake), mice 
in the vehicle and BIBP3226 groups had significantly higher food intakes than those in 
the E2 and the combination treatment groups (same result as that shown in Table 7): 1.32 
g of food for the vehicle group, 1.46 g of food for the BIBP3226 group, 0.83 g of food for 
the E2 group, and 0.78 g for the combination treatment group.   
There was significant time by treatment interaction effect (p-value< 0.001, Table 
9), indicating that the treatment group averages were not shifting uniformly from week 1 
and week 2 (Table 7; Figures 9, 10).  Results from week 1 averages of food intake reveal 
that mice in the vehicle and BIBP3226 treatment groups consumed significantly more 
than mice in the E2 and combination treatment groups (results shown in Table 8).  
Similarly, week 2 averages of food intake indicate that mice in the vehicle and BIBP3226 
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treatment groups consumed significantly more than mice in the E2 and combination 
treatment groups.  Mice in the vehicle and BIBP3226 groups consumed significantly 
more between week 1 and week 2:  mice in the vehicle group consumed an average of 
1.08 g of food in week 1 and 1.66 g in week 2, and mice in the BIBP3226 treatment 
group consumed an average of 1.01 g of food in week 1 and 1.92 g in week 2.  There was 
no significant change in average daily food intake for mice in the E2 and combination 
treatment groups from week 1 to week 2 (Table 8).  
 
 
TABLE 9:  F and p values for time and treatment effects on average food intake.  
         Same results as in Table 3.  
 
 
 
 
 
 
 
 
End of Week Food Intake for Week 1 and Week 2 
 A comparison of mean food intakes on day 7 versus those on day 14 generated 
results similar to those for weekly averages (Table 10).  Time and treatment effects were 
statistically significant (p-value= 0.003, Table 10).  As in the analysis of overall weekly 
averages, mice ate more food (approximately 0.16 g) on day 14 than they did on day 7 
(Table 11).  Moreover, as before, food intake of mice in the vehicle and BIBP3226 
groups ate more than mice in the E2 and combination treatment groups (Table 12).   
Effect p-value 
Time <0.001 (see Figure 7, Table 6)
Treatment <0.001 (see Figure 8, Table 7)
Time x Treatment <0.001 (see Figure 9, Table 8)
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The between-subjects analysis revealed a significant treatment effect, i.e., end of 
week food intake was not uniform for the 4 groups (p-value<0.001, Table 10).  A strong 
within-subject effect was evident for end of week food intake comparing week 1 to week 
2 indicating food intake shifted significantly between weeks (p-value=0.006, Table 11).  
End of week average food intake of ob/ob mice given vehicle or BIBP3226 were 
statistically equivalent (Table 12): 1.24 g of food per day for the vehicle group and 1.39 g 
of food per day for the BIBP3226 group.  Food intakes by estradiol-treated mice were 
statistically equivalent to that of mice in the combination treatment (Table 12):  0.67 g of 
food per day for the estradiol group versus 0.60 g of food per day for the combination 
group.  There was a significant time by treatment interaction (p-value=0.003, Table 12) 
indicating that the end of week food intake averages were not shifting uniformly from 
week 1 and week 2.  Statistical results support the formation of two homogenous subsets, 
one subset including vehicle and BIBP3226 treatments, where mice consumed more from 
the end of week 1 to the end of week 2, and the other subset including E2 and 
combination treatments, where food consumed by mice did not change significantly from 
end of week 1 to end of week 2 (Table 13, Figure 10).   
 
 
TABLE 10:  F and p values for end of week food intake for week 1(days 28 to 34) and 
                      week 2 (days 35 to 41). 
 
  
  
  
  
 
 
Effect F-value p-value 
Time F (1,55)= 8.200 0.006 (Table 9) 
Treatment F (3,55)=32.627 <0.001 (Table 10) 
Time x Treatment F (3,55)=5.196 0.003 (Table 11) 
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TABLE 11:  End of week food intake for week 1 and week 2.  
                                 a,b Means with different superscript letters are significantly different. 
 
Week n End of Week Food Intake;Mean (±SEM) g/day 
1 59 0.90 (±0.06) a 
2 59 1.06 (±0.07) b 
 
 
 
TABLE 12:  Food intake averages for end of week 1 and end of week 2, by treatment 
                      group.  a,b Means with different superscript letters are significantly different. 
Treatment n Food Intake for Total (End of Both Weeks); Mean (±SEM) g/day 
Vehicle 14 1.24 (±0.17)a 
E2 15 0.67 (±0.07) b 
BIBP3226 15 1.39 (±0.13) a 
Combination 15 0.60 (±0.05) b 
 
 
 
TABLE 13:  End of week food intake for weeks 1 & 2 by treatment group. 
           a,b,c Means with different superscript letters are significantly different. 
 
Treatment n End of Week 1 Food Intake;Mean (±SEM) g/day 
End of Week 2 Food Intake;
Mean (±SEM) g/day 
Vehicle 14 1.05 (±0.10) a 1.44 (±0.06) c 
E2 15 0.70 (±0.07) b 0.63 (±0.07) b 
BIBP3226 15 1.25 (±0.15) a 1.53 (±0.11) c 
Combination 15 0.61 (±0.08) b 0.58 (±0.07) b 
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Body Mass Analysis 
Repeated Measures ANOVA of body mass indicated a statistically significant 
time effect on body mass over the 14 day experiment (Figure 11, Table 14).  As expected, 
all mice gained weight over the 14 day experiment.   To discern more precisely the time 
course of response to these treatments, additional analyses were conducted.  An 
inspection of Figure 12 suggested that it would be productive to compare week one with 
week two.  Similar to analyses in Daily Food Intake, two different comparisons were 
made.  The first comparison included a statistical analysis comparing data from the 
averages of week one with the averages of week two.  In the second comparison, body 
mass data from the end of week one was compared with data from the end of week two.  
 
  
Average Body Mass of Week 1 with Week 2 
 
 A repeated measures ANOVA was used to analyze the effects of treatment 
(vehicle, E2, BIBP3226, or combination) on body mass over time.  Test of within-
subjects effects indicate significant time effect where body mass was not uniform for the 
4 groups.  A within-subject effect was evident for average body mass over week 1 and 
week 2 indicating body mass shifted significantly (p-value<0.001, Table 14).  Time 
(Tables 14, 15; Figure 11) had a significant effect on average body mass:  comparing 
week 2 to week 1, the average body mass of week 2 (30.10 g) was greater than that of 
week 1(26.75 g) across all treatment groups (p-value<0.001).  This suggests that 
treatment did not interfere with weight gain expected as the young animals matured.  
Drug treatment did not result in a significant effect on average body mass between 
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treatment groups between week 1 and week 2, though mice in the vehicle and BIBP3226 
treatment groups weighed more than mice in the E2 and combination treatment groups (p-
value=0.328, Tables 14, 16; Figure12).  Moreover, the interaction of time and treatment 
was not statistically significant for average body mass (p-value=0.721, Tables 14, 17; 
Figure 13).   
 
 
TABLE 14:  F and p values for average body mass. 
 
    
 
FIGURE 11:  Change in body mass by age for all mice.  Across the duration of  
                        the experiment all animals increased body mass 
Effect F-value p-value 
Time F (1,55)= 44.198 <0.001 (see Figure 10, Table 13) 
Treatment F (3,55)=1.173 0.328 (see Figure 11, Table 14) 
Time x Treatment F (3,55)=0.446 0.721(see Figure 12, Table 15) 
 
 
 
 
 
 
41 
 
 
TABLE 15:  Average body mass for week 1 and week 2. 
                      a,b Means with different superscript letters are significantly different. 
Week n Average Body Mass
1 59 26.75 (±0.16) a 
2 59 30.10 (±0.18) b 
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FIGURE 12:  Mean body mass for each treatment group. 
 
 
TABLE 16:  Average body mass by treatment group.  
                                 a,b Means with different superscript letters are significantly different. 
                     
 
Treatment n Average Body Mass
Vehicle 14 29.25 (±0.33) a 
E2 15 27.68 (±0.24) a 
BIBP3226 15 28.95 (±0.25) a 
Combination 15 27.86 (±0.22) a 
 
 a 
   a 
 a 
  a 
               Vehicle                                E2                               BIBP3226                 Combination 
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FIGURE 13:  Body mass by age for each treatment group. 
 
 
 
TABLE 17:  Average body mass for weeks 1 & 2 by treatment group. 
                      a,b Means with different superscript letters are significantly different. 
 
Treatment n Week 1 Average Body Mass Week 2 Average Body Mass
Vehicle 14 27.26 (±0.37)a 31.23 (±0.40) b 
E2 15 26.36 (±0.30) a 29.02 (±0.46) b 
BIBP3226 15 26.94 (±0.29) a 30.96 (±0.30) b 
Combination 15 26.46 (±0.28) a 29.27 (±0.28) b 
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End of Week Body Mass Measurements for Week 1 and Week 2 
Time had a significant effect on end-of-week body mass between week 1 and 
week 2 (p-value <0.001, Tables 18, 21); as before, body mass increased at the end of 
week 2.  Though a statistically significant difference did not exist between treatment 
groups, mice in the vehicle and BIBP3226 combination treatment groups weighed more 
than those in the E2 and combination treatment groups.  A strong within-subject effect 
was evident for end of week body mass between week 1 and week 2 indicating body 
mass shifted significantly with a p-value < 0.001 (Tables 18, 19): overall end of week 
body mass for week 1 was 28.06 g versus 31.42 g for week 2.  Treatment alone did not 
have a significant effect on end of week or mean body mass (Tables 20, 21). Time and 
treatment did have a statistically significant interaction effect on end of week body mass 
between week 1 and week 2 where body mass shifted significantly for all groups with a 
p-value <0.001 (Table 18 & 22).  
 
 
TABLE 18:  F and p values for end of week body mass. 
 
 
 
 
 
 
 
 
 
 
Effect F-value p-value 
Time F (1,55)= 925.854 <0.001 (see Figure 10, Table 17) 
Treatment F (3,55)=1.474 0.232 (see Figure 11, Table 18) 
Time x Treatment F (3,55)=8.322 <0.001 (see Figure 12, Table 20) 
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TABLE 19:  End of week body mass for week 1 and week 2. 
                      a,b Means with different superscript letters are significantly different. 
 
Week n End of Week Body Mass
1 59 28.06 (±0.42)a 
2 59 31.42 (±0.48) b 
 
 
 
TABLE 20:  Total end of week body mass by treatment group. 
                      a Means with different superscript letters are significantly different. 
 
Treatment n End of Week Body Mass
Vehicle 14 29.77 (±0.91) a 
E2 15 28.76 (±0.62) a 
BIBP3226 15 30.51 (±0.65) a 
Combination 15 28.92 (±0.56) a 
 
 
 
TABLE 21:  Mean body mass for ob/ob treatment groups at day 41. 
                      a Means with different superscript letters are significantly different. 
 
Treatment n Mean Body Mass
Vehicle 14 29.25 (±0.33) a 
E2 15 27.68 (±0.24) a 
BIBP3226 15 28.95 (±0.25) a 
Combination 15 27.86 (±0.22) a 
 
 
 
TABLE 22:  End of week body mass for weeks 1 & 2 by treatment group. 
           a,b Means with different superscript letters are significantly different. 
  
Treatment n End of Week 1 Body Mass End of Week 2 Body Mass
Vehicle 14 28.84 (±1.08)a 32.83 (±1.34) b 
E2 15 27.38 (±0.79) a 30.13 (±0.97) b 
BIBP3226 15 28.59 (±0.77) a 32.44 (±0.83) b 
Combination 15 27.48 (±0.72) a 30.37 (±0.71) b 
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Uterine Mass Analysis and Reproductive Behavior 
 One-way ANOVA indicated a statistically significant treatment effect on uterine 
mass. Subsequently, a pair-wise comparison with Duncan’s Multiple Range test resulted 
in the distinction of three groups of mice.  In the first group, the average uterine masses 
of mice which received vehicle injections or BIBP3226 injections were homogenous, low 
and statistically equivalent: 24.5 mg for the vehicle group and 24.2 mg for the BIBP3226 
group (Table 23, Figure 14).  In the second group, the average uterine mass of mice 
which received E2 only was 53.2 mg and significantly greater than those in the first group 
(Table 23).  Finally, a third group of mice, those which received the combination 
treatment had the highest uterine mass at 92.1 mg (Figure 14).  Following overnight 
cohabitation on day 14 with a stud male, a vaginal plug was evident in each female 
mouse that had received E2 or the combination treatment, but none of the females in the 
vehicle or the BIBP3226-only group mated (Table 24). 
 
TABLE 23:  Mean (± SEM) adjusted uterine mass (mg of uterine mass/ 25g body mass)  
           at age 44 days (n=number of mice per treatment group). 
           a,b,c Means with different superscript letters are significantly different. 
 
Treatment n Uterine Mass;  Mean(±SEM) mg/25g body mass
Vehicle 14 24.5 (±0.9) a 
E2 15 53.2 (±3.9) b 
BIBP3226 15 24.2 (±2.0) a 
Combination 15 92.1 (±5.3) c 
Treatment Effect, F(3,54)= 84.48, p<0.001 
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FIGURE 14:  The effects of drug treatment on uterine mass in leptin-deficient female 
             mice.  Different letters indicate statistically significant differences. 
 
 
 
TABLE 24:  Presence or absence of vaginal plug in female mice following 12 hours with 
                      stud male (n=number of mice per treatment group). 
 
Treatment n Percent of females with  vaginal plug 
Vehicle 14 0% 
E2 15 100% 
BIBP3226 15 0% 
Combination (17-β Estradiol & BIBP3226) 15 100% 
   
 
 
 
 
 
  Vehicle                               E2                           BIBP3226                  Co bination 
 a  a 
  b 
 c 
 
 
 
 
 
 
47 
 
 
CHAPTER IV 
DISCUSSION 
 
  
This project evaluates the effects of peripheral NPY Y1 receptor blockade and 
exogenous estradiol activity in prepubertal leptin-deficient female mice while assessing 
appetite regulation, body mass and reproductive development and behavior.  
The premise for using the BIBP3226 compound, an NPY Y1 receptor antagonist, 
to impair peripheral NPY Y1 receptor activity is the proposed antagonistic relationship 
between the leptin and the NPY signaling pathways.  Leptin is a protein that signals 
satiety in hypothalamic networks as part of a physiological mechanism to maintain an 
optimal body mass.  Conversely, NPY is a signal that activates appetite via its 
interactions with various receptors throughout the central, and possible the peripheral, 
nervous system.   Regions of the ARC in the hypothalamus are heavily innervated with 
both leptin and a variety of NPY receptors.  Clarifying the specific roles of the NPY sub-
receptors and their influence on appetite, body mass and reproductive development and 
behavior would be a significant breakthrough in decoding the complex signaling network 
that maintains energy homeostasis.   
Ovarian sex steroid hormones, especially E2, play a crucial role in normal 
reproductive development.  The estrogens have anorexigenic consequences, much like 
leptin, that influence energy homeostasis.  Though estrogen receptors are broadly 
distributed, E2’s direct mode of action to decrease body mass is thought to result from its 
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interactions with the leptin pathway.  In addition, E2 might cause an increase in energy 
expenditure with or without its proposed interactions on the leptin pathway and appetite.   
Utilizing a model with a specific disruption in the leptin signaling pathway, and 
consequent changes in NPY and other pathways, allowed me to examine the role of such 
pathways in regulating appetite, body mass and reproductive behavior.  Likewise, this 
ob/ob mouse model allowed me to assess the influence of Y1 activity in the presence and 
absence of active estrogen.  
 
Neuropeptide Y 
NPY mediates its effects by binding its receptors; however, the search for the 
central and peripheral locations of each of the six NPY receptor subtypes is ongoing.  By 
targeting a specific receptor, i.e., NPY Y1 receptor, I examined the receptors’ role in 
metabolism and reproduction.  Theory holds that the absence of leptin causes a chronic 
elevation of NPY and hyperphagia, and diminished energy expenditure, both of which 
contribute to an obese phenotype.  
Based on the results reported here, the NPY Y1 receptors in the periphery are 
unlikely candidates in mediating the orexigenic effects of NPY on appetite and body 
mass. The NPY Y1R antagonist, BIBP3226, failed to reduce hyperphagia and body mass.  
It is possible that the central Y1 receptors were not antagonized by the peripheral 
administration of BIBP3226.  Future studies could examine the effects of central 
administration (intracerebroventricular injections) of BIBP3226 in the ob/ob model. 
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Though ob/ob mice administered the Y1 receptor antagonist, BIBP3226, weighed 
slightly less than mice administered vehicle, the differences were not statistically 
significant.  Summarizing BIBP3226’s effects on food intake and body mass, there were 
no significant effects of BIBP3226 when delivered alone.  As noted earlier, CNS 
administration of BIBP3226 might produce different results.   
Research suggesting that Y1 receptor activity prevents reproductive organ 
development as well as reproductive behavior was supported by the results of this 
experiment as previously hypothesized.  Ob/ob mice treated only with BIBP3226 did not 
exhibit uterine hypertrophy nor did they exhibit reproductive behavior characterized by a 
vaginal plug following 12 hour behavioral test with stud males.  Endogenous E2 signaling 
is directly controlled by the hypothalamic pituitary gonadal axis, and in the absence of E2 
signaling, BIBP3226 had no direct effects on uterine development.   However, in the 
presence of E2, as in the combination treatment group, BIBP3226 caused significant 
uterine hypertrophy than did E2 treatment alone.  This finding was consistent with my 
hypothesis that the combination treatment would have additive effects on reproductive 
development. 
 
17-β Estradiol 
 
 Whether by itself or in combination with the NPY-Y1R antagonist, E2 exerted its 
expected stimulatory effects on uterine hypertrophy and on sexual receptivity.   
Moreover, E2 reduced food intake and body mass in the same pattern.  
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Following 14 days of treatment, all mice treated with E2, whether E2 only or the 
combination group, exhibited significantly greater uterine mass than those in the vehicle 
or BIBP3226 treatment groups.  As expected, and consistent with my hypothesis, E2 did 
exert uterotrophic effects in the ob/ob mouse model.  This finding suggests that 
disturbances in hypothalamic peptide levels, specifically leptin and NPY, lead to a 
reduction in endogenous E2 release, resulting in the reproductive impairments 
characteristic of the ob/ob mice.  Though both the E2 and the combination treatment 
groups unanimously exhibited lordosis, as evidenced by vaginal plugs, the presence of 
exogenous E2 appears to have a greater effect on reproductive behavior than did 
BIBP3226.  This finding is supported in that 100% of mice in the E2 and combination 
treatment groups exhibited copulatory behavior, but the BIBP3226 treatment alone was 
insufficient to stimulate lordosis when female mice were partnered with their stud male in 
the 12 hour behavioral test.   
Exogenous E2 reduced food intake and body mass over the 14 day treatment 
period in this study:  the leptin-deficient mice administered E2 exhibited significantly 
lower food consumption than did mice in the vehicle and BIBP3226 treatment groups.  
This finding supports my hypothesis that E2 exerts anorexigenic effects on food intake in 
leptin-deficient mice.    
 The pubertal transition in mice occurs during a phase of somatic growth, so it’s no 
surprise that mice in all four treatment groups gained weight, as expected, over the 
duration of the experiment.  However, E2 did not significantly reduce body mass 
compared to the vehicle, BIBP3226 and combination treatment groups over the 14 day 
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treatment.  In future studies, extending the treatment period or increasing the dosage 
might result in a significant E2 effects on body mass.   
 
Combination Treatment 
 NPY-influenced aspects of reproductive development are linked to the presence 
of sex steroids, as my findings suggest an uterotrophic role for NPY Y1 receptor 
blockade only when E2 was added.  Uterine growth was evident in all mice who received 
either the E2 or the combination treatment, though the uterine development was 
significantly more pronounced in mice which received the combination treatment.  This 
finding supported my hypothesis that peripheral Y1 receptor blockade can contribute to 
reproductive organ development.  Likewise, all (100%) mice who received the 
combination treatment exhibited copulatory behavior as evidenced by a seminal plug.  
This “ceiling effect” prohibits discernment of a separate role for Y1 receptor blockade.  
However, in the absence the E2, the Y1 receptor antagonist had no significant effect on 
reproductive development and behavior.  The presence of E2 appears necessary to induce 
the peripheral effects of BIBP3226 on Y1 receptors to stimulate reproductive organ 
development and behavior, where BIBP3226 alone was insufficient to stimulate 
reproductive development and elicit reproductive behavior.  Research by Hill et al. 
supports a role for E2 in reducing Y1 receptor mRNA, where female rodents administered 
estrogen in vivo exhibited a decrease in Y1R mRNA [48].  This finding, in combination 
with research indicating that E2 increases excitatory inputs to POMC neurons, the 
precursor to α-MSH, may explain, in part, the additive effects of the combination 
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treatment on uterine mass results [34].  Moreover, the combined treatment effects of E2 
and BIBP3226 supports my hypothesis that an interaction between E2 and the Y1 
receptor subtype exists and that simultaneous activation of the E2 path and inactivation of 
the Y1 receptor path mediates reproductive organ development, as evidenced by the 
combination treatment group having a significantly higher average uterine weight than 
the E2 only treated group.   
Mice in the combination treatment group exhibited a lower average food intake 
than did the E2 only treated mice, but this difference was not significantly different.  The 
results of this experiment do support my hypothesis that E2 has anorexigenic effects on 
food intake leading to reduced body mass, though the Y1 receptor antagonist did not 
elevate the effects of E2 as was expected to occur in the combination treatment group.  
This finding may be explained by a different NPY receptor subtype, other than the Y1, in 
mediating the orexigenic actions of NPY. 
Body mass of the combination treatment mice was less than those of mice which 
received either vehicle or BIBP3226-only.  However, the combination treatment did not 
have greater effects in reducing body mass than E2 alone.  This finding suggests that a 
continued combination treatment may result in a significantly lower body mass during an 
extended treatment interval than did vehicle and BIBP3226 treatments.  Moreover, an 
extended treatment period may support a sex steroid dependent mechanism for NPY on 
adipocytes as well as reproductive organs. The presence of active estrogen may be 
required to limit the anti-lipolytic actions of NPY, as results indicate that the combination 
treatment group had a reduced body mass compared to the BIBP3226 treatment only.  
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Future studies could examine the effects of central administration of BIBP3226 in 
combination with E2 to reduce body mass in the ob/ob mice.   
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CHAPTER V 
CONCLUSION 
 
 
 In conclusion, exogenous E2 does appear to have a dual function in both energy 
homeostasis, with anorexigenic actions similar to that of leptin, and reproductive 
development, where reproductive growth is enhanced by the presence of a NPY Y1 
receptor antagonist.  Peripherally administered E2 and NPY Y1R antagonist, BIBP3226, 
stimulate reproductive (uterine) development in ob/ob mice.  Consequently, E2 or 
combination treatments promote copulatory behavior in this leptin-deficient model.  
Exogenous E2 does lead to reductions in appetite and body mass, but BIBP3226 
treatments alone do not successfully minimize caloric intake or body mass in ob/ob mice.  
From these experimental findings, I conclude that the Y1 receptor activity does not 
mediate its effects on energy homeostasis, but rather reproductive development and 
behavior, and these reproductive changes are E2 dependent.  In addition, exogenous E2 
does play a vital role in appetite and body mass regulation and reproductive ability 
whether administered alone or in combination with NPY Y1R antagonist.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
REFERENCES 
 
 
 
[1]  Schwartz M., Porte Daniel.  Diabetes, obesity and the brain.  Science; 307: 375-379. 
 
[2]  Munzberg H., Myers M.  Molecular and anatomical determinants of central leptin 
resistance. Nature Neuroscience.  2005; 8: 566-570. 
 
[3]  Horvath T.  The hardship of obesity: a soft-wired hypothalamus.  Nature 
Neuroscience. 2005. 
 
[4]  Sahu A.  Leptin signaling in the hypothalamus: emphasis on energy homeostasis and 
leptin resistance.  Frontiers in Neuroendocrinology.  2004; 24: 225-253. 
 
[5]  Horvath T., Bruning J.  Developmental programming of the hypothalamus: a matter 
of fat.  Nature Medicine.  2006; 12: 52-53.   
 
[6]  Simerly R.  Wired on hormones: endocrine regulation of hypothalamic development.  
Current Opinion in Neurobiology.  2005; 15: 81-85. 
 
[7]  Pinto S., Roseberry A., Lie H., Diano S., Shanabrough M., Cai X., Friedman J., 
Horvath T.  Rapid rewiring of the arcuate nucleus feeding circuits by leptin.  Science.  
2004; 304: 110-115. 
 
[8]  Sebastien G., Draper S., Simerly R.  Trophic action of leptin on hypothalamic 
neurons that regulate feeding.  Science.  2004; 304: 108-110. 
 
[9]  Cone R.  Anatomy and regulation of the central melanocortin system.  Nature.  2005; 
8(5): 571-578. 
 
[10]  Gonzales C., Voirol M., Giacomini M., Gaillard R., Pedrazzini T., Pralong F.  The 
neuropeptide Y Y1 receptor mediates NPY-induced inhibition of the gonadotrope axis 
under poor metabolic conditions.  FASEB J.  2004; 18: 137-139. 
 
[11]  Leibowitz S., Akabayashi A., Alexander J., Wang  J.  Gonadal steroids and 
hypothalamic galanin and neuropeptide y: role in eating behavior and body weight 
control in female rats.  Endocrinology.  1998; 139 (4): 1771-1780. 
 
[12]  Kalra S., Kalra P.  NPY and cohorts in regulating appetite, obesity and metabolic 
syndrome: beneficial effects of gene therapy.  Neuropeptides.  2004; 38: 201-211. 
 
 
 
 
 
 
 
56 
 
[13]  Wade G., Jones J.  Neuroendocrinology of nutritional infertility.  Am J Physiol 
Regul Integr Comp Physiol.  2004; 287: 1277-1296. 
 
[14]  Wade G., Schneider J.  Metabolic fuels and reproduction in female mammals.  
Neuroscience and Biobehavioral Reviews.  1992; 16: 235-272. 
 
[15]  Diamanti-Kandarakis E., Bergiele A.  The influence of obesity on 
hyperandrogenism and infertility in the female.  Obesity Reviews.  2001; 2: 231-238. 
 
[16]  Jones M., Thorburn A., Britt K., et al.  Aromatase deficient (ArKO) mice have a 
phenotype of increased adiposity.  Proceedings of the National Academy of Sciences, 
USA.  2000; 97: 12735-12740. 
 
[17]  Jones M, Thorburn A., Britt K, et al.  Aromatase-deficient (ArKO) mice accumulate 
excess adipose tissue.  Journal of Steroid Biochemical Molecular Biology.  2001; 79: 3-9. 
 
[18]  Sahu A.  Leptin decreases food intake induced by melanin-concentrating hormone 
(MCH), galanin (GAL) and neuropeptide Y (NPY) in the rat.  Endocrinology.  1998; 139: 
4739-4742. 
 
[19]  Bradley R., Mansfield J., Maratos-Flier E.  Neuropeptides, including neuropeptide 
Y and melanocortins, mediate lipolysis in murine adipocytes. Obesity Research.  2005; 
13: 653-661. 
 
[20]  Gehlert D.  Introduction to the reviews on neuropeptide Y.  Neuropeptides.  2004; 
38: 135-140. 
[21]  Puder J., Monaco S., Gupta S., Wang J., Ferin M., Warren M. Estrogen and exercise 
may be related to body fat distribution and leptin in young women.  Fertility and Sterility.  
2006; 86(3): 694-699. 
 
[22]  Sisk C., Foster D.  The neural basis of puberty and adolescence.  Nature 
Neuroscience.  2004; 7(10): 1040-1047. 
 
[23]  Neary N., Goldstone A., Bloom S.  Appetite regulation: from the gut to the 
hypothalamus.  Clinical Endocrinology.  2004; 60: 153-160.   
 
[24]  Walczewska A., Yu W., Karanth S., McCann S. Estrogen and leptin have 
differential effects on FSH and LH release in female rats.  Society for Experimental 
Biology and Medicine.  1999; 222: 170-177. 
 
[25]  Pralong F., Gonzales C., Voirol M., Palmiter R., Brunner H., Gaillard R., Seydoux 
J., Pedrazzini T.  The neuropeptide Y Y1 receptor regulates leptin-mediated control of 
energy homeostasis and reproductive functions.  FASEB J.  2002; 16: 712-714. 
 
 
 
 
 
 
57 
 
 
[26]  Tritos N., Segal-Lieberman G., Vezeridis P., Maratos-Flier E.  Estradiol-induced 
anorexia is independent of leptin and melanin-concentrating hormone.  Obesity Research.  
2004; 12(4): 716-724. 
 
[27]  Dubuc P.  Effects of estrogen on food intake, body weight and temperature of male 
and female obese mice.  Proceedings of the Society for Experimental Biology and 
Medicine.  1985; 180: 468-473.   
 
[28]  Schneider J., Wade G.  Availability of metabolic fuels controls estrous cyclicity of 
Syrian hamsters.  Science.  1989; 244: 1326-1328. 
 
[29]  Ainslie D., Morris M., Wittert G., Turnbull H., Proietto J., Thorburn A.  Estrogen 
deficiency causes central leptin insensitivity and increased hypothalamic neuropeptide Y.  
International Journal of Obesity.  2001; 25: 1680-1688. 
 
[30]  Wade G., Lempicki R., Panicker A., Frisbee R., Blaustein J.  Leptin facilitates and 
inhibits sexual behavior in female hamsters.  American Physiological Society.  1997; 
1354-1358.   
 
[31]  Wade G., Gray J.  Gonadal effects on food intake and adiposity: a metabolic 
hypothesis.  Physiology and Behavior.  1979; 22: 583-593. 
 
[32]  Mayes J., Watson G.  Direct effects of sex steroid hormones on adipose tissues and 
obesity.  Obesity.  2004; 5: 197-216. 
[33]  Rocha M., Bing C., Williams G., Puerta M.  Physiologic estradiol levels enhance 
hypothalamic expression of the long from of the leptin receptor in intact rats.  The 
Journal of Nutritional Biochemistry.  2004; 12: 328-334. 
 
[34]  Gao Q., Mezei G., Nie Y., Rao Y., Choi C., Bechmann I., Leranth C., Toran-
Allerand D., Priest C., Roberts J., Gao X., Mobbs C., Shulman G., Diano S., Horvath T.  
Anorectic estrogen mimics leptin’s effect on the rewiring of melanocortin cells and Stat 3 
signaling in obese animals.  Nature Medicine.  2007; 13(1): 89-94. 
 
[35]  Geary N., Asarian L., Korach K., Pfaff D., Ogawa S.  Deficits in E2-dependent 
control of feeding, weight gain, and cholecystokinin satiation in ER-alpha null mice.  
Endocrinology. 2001; 142: 4751-4757. 
 
[36]  Eckel L.  Estradiol: a rhythmic, inhibitory, indirect control of meal size.  Physiology 
and Behavior.  2004; 82: 35-41.  
 
 
 
 
 
 
 
58 
 
[37]  Heine P., Taylor J., Iwamoto G., Lubahn D., Cooke P.  Increased adipose tissue in 
male and female estrogen receptor-alpha knockout mice.  Proceedings of the National 
Academy of Sciences, USA.  2000; 97: 12729-12734. 
 
[38]  Pelleymounter M., Baker M., McCaleb M.  Does estradiol mediate leptin’s effects 
on adiposity and weight gain?  Endocrinology and Metabolism.  1999; 276: 955-963. 
 
[39]  Musso R., Maggi A., Eva C.   17β-Estradiol stimulates mouse neuropeptide Y-Y1 
receptor gene transcription by binding to estrogen receptor alpha in neuroblastoma cells.  
Neuroendocrinology. 2000; 72: 360-367. 
 
[40]  DiCarlo C., Tommaselli G., Nappi C.  Effects of sex steroid hormones and 
menopause on serum leptin concentrations.  Gynecological Endocrinology.  2002; 16: 
479-491. 
 
[41]  Butler A., Cone R.  The melanocortin receptors: lessons from knockout models.  
Neuropeptides.  2002; 36: 77-84.   
 
[42]  Parker E., Heek M., Stamford A.  Neuropeptide Y receptors as targets for anti-
obesity drug development: perspective and current status.  European Journal of 
Pharmacology.  2002; 440: 173-187.   
 
[43]  Stephens T., Basinski M., Bristow P., Bue-Valleskey J., Burgett S., Cragt L., Hale 
J., Hoffmann J., Hsiung H., Kriauciunas A., MacKellar W., Rosteck P., Schonier B., 
Smith D., Tinsley F., Zhang W., Heiman M.  The role of neuropeptide Y in the 
antiobesity action of the obese gene product.  Nature. 1995; 377: 530-532. 
 
[44]  Raposinho P., White R., Aubert M.  The melanocortin agonist melanotan-II reduces 
the orexigenic and adipogenic effects of neuropeptide Y but does not affect the NPY-
driven suppressive effects on the gonadtropic and somatotropic axes in the male rat.  
Journal of Neuroendocrinology.  2003; 15: 173-81. 
 
[45]  Egawa M., Yoshimatsu H., Bray G.  Neuropeptide Y suppresses sympathetic 
activity to interscapular brown adipose tissue in rats.  American Journal of Physiology.  
1991; 260: 328-334. 
 
[46]  Della-Zuana O., Revereault L., Beck-Sickinger A., Monge A., Caignard D., 
Fauchere J., Henlin J., Audinot V., Boutin J., Chamorro S., Feletou M., Levens N.  A 
potent and selective NPY Y5 antagonist reduces food intake but not through blockade of 
the NPY Y5 receptor.  International Journal of Obesity.  2004; 28: 628-639.      
 
[47]  Jones J., Pick R., Dettloff S., Wade G.  Metabolic fuels, neuropeptide Y, and estrous 
behavior in Syrian hamsters.  Brain Research.  2004; 1007: 78-85. 
 
 
 
 
 
 
59 
 
 
[48]  Hill J., Urban J., Xu M., Levine J.  Estrogen induces neuropeptide y (NPY) Y1 
receptor gene expression and responsiveness to NPY in gonadotrope-enriched pituitary 
cell cultures.  Endocrinology.  2004; 145(5): 2283-2290. 
 
[49]  Pedrazzini T.  Importance of NPY Y1 receptor-mediated pathways; assessment 
using NPY Y1 receptor knockouts.  Neuropeptides.  2004; 38: 267-75. 
 
[50]  Kalra S.  Mandatory neuropeptide-steroid signaling for preovulatory luteinizing 
hormone-releasing hormone discharge.  Endocrinology.  1993; 14: 507-538. 
 
[51]  Labelle M., Boulanger Y., Fournier A., St. Pierre S., Savard R.  Tissue-specific 
regulation of fat cell lipolysis by NPY in 6-OHDA-treated rats.  Peptides. 1997; 18: 801-
808.   
 
[52]  Margareto J., Aguado M., Oses-Prieto J.  A new NPY-antagonist strongly stimulates 
apoptosis and lipolysis on white adipocytes in an obesity model.  Life Science.  2000; 68: 
99-107. 
 
[53]  Bradley, R., Kokkotou E., Maratos-Flier E., Cheatham B.  Melanin-concentrating 
hormone activates signaling pathways in 3T3-L1 adipocytes.  Am J Physiol Endocrinol 
Metab.  2002; 49: 1073-1077. 
 
[54]  Olster D., Auerbach I.  Deficits in progesterone-facilitated sexual behaviors and 
forebrain estrogen and progestin receptors in obese female zucker rats.  
Neuroendocrinology.  2000; 72: 350-359. 
 
[55]  Anwar A., McTernan P., Anderson L., Askaa J., Moody C., Barnett A., Eggo M., 
Kumar S.  Site-specific regulation of oestrogen receptor-α and –β by oestradiol in human 
adipose tissue.  Diabetes, Obesity and Metaboism.  2001; 338-349. 
 
[56]  Pederson S., Kristensen K., Hermann P., Katzenellenbogen J., Bjorn R.  Estrogen 
controls lipolysis by up-regulating α2A-adrenergic receptors directly in human adipose 
tissue through the estrogen receptor α.  Implications for the female fat distribution.  The 
Journal of Clinical Endocrinology & Metabolism.  2004; 1869-1878.   
 
[57]  Rassokhin D., Agrafiotis D.  Kolmogorov-Smirnov statistic and its application in 
library design.  Journal of Molecular Graphics and Modelling.  2000; 18:368-382. 
 
